Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 22, 2013 - Issue 7
Submit an article Journal homepage
551
Views
30
CrossRef citations to date
0
Altmetric
Reviews

ATP-noncompetitive CDK inhibitors for cancer therapy: an overview

Agnese Anna AbateSbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, [email protected]
,
Francesca PentimalliIstituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS – Italia
,
Luca EspositoIstituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione Giovanni Pascale” – IRCCS – Italia
&
Antonio GiordanoSbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, [email protected];Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy
Pages 895-906 | Published online: 04 Jun 2013

Citations (30)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Basharat Ahmed, Sara Khan, Faisal Nouroz, Umar Farooq & Saba Khalid. (2022) Exploring multi-target inhibitors using in silico approach targeting cell cycle dysregulator–CDK proteins. Journal of Biomolecular Structure and Dynamics 40:19, pages 8825-8839.
Read now
Carmen Criscitiello, Giulia Viale, Angela Esposito & Giuseppe Curigliano. (2014) Dinaciclib for the treatment of breast cancer. Expert Opinion on Investigational Drugs 23:9, pages 1305-1312.
Read now

Articles from other publishers (28)

Basma S. Almansour, Faizah A. Binjubair, Alaa A.-M. Abdel-Aziz & Sara T. Al-Rashood. (2023) Synthesis and In Vitro Anticancer Activity of Novel 4-Aryl-3-(4-methoxyphenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridines Arrest Cell Cycle and Induce Cell Apoptosis by Inhibiting CDK2 and/or CDK9. Molecules 28:17, pages 6428.
Crossref
Zhouling Xie, Shuzeng Hou, Xiaoxiao Yang, Yajun Duan, Jihong Han, Qin Wang & Chenzhong Liao. (2022) Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts. Journal of Medicinal Chemistry 65:9, pages 6356-6389.
Crossref
Junsha An, Cheng Peng, Xiaofang Xie & Fu Peng. (2022) New Advances in Targeted Therapy of HER2-Negative Breast Cancer. Frontiers in Oncology 12.
Crossref
Yi Liu, Leilei Fu, Junhao Wu, Ming Liu, Guan Wang, Bo Liu & Lan Zhang. (2022) Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy. European Journal of Medicinal Chemistry 229, pages 114056.
Crossref
Ahmed Mohamed Etman, Sherif Sabry Abdel Mageed, Mohamed Ahmed Ali & Mahmoud Abd El Monem El Hassab. (2021) Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story. Current Chemical Biology 15:2, pages 139-162.
Crossref
Michela Piezzo, Paolo Chiodini, Maria Riemma, Stefania Cocco, Roberta Caputo, Daniela Cianniello, Germira Di Gioia, Vincenzo Di Lauro, Francesca Di Rella, Giuseppina Fusco, Giovanni Iodice, Francesco Nuzzo, Carmen Pacilio, Matilde Pensabene & Michelino De Laurentiis. (2020) Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences 21:17, pages 6400.
Crossref
Marion Peyressatre, Dominique Patomo Arama, Arthur Laure, Juan A. González-Vera, Morgan Pellerano, Nicolas Masurier, Vincent Lisowski & May C. Morris. (2020) Identification of Quinazolinone Analogs Targeting CDK5 Kinase Activity and Glioblastoma Cell Proliferation. Frontiers in Chemistry 8.
Crossref
Mark A. Klein. 2020. 115 141 .
Mai Maher, Asmaa E. Kassab, Ashraf F. Zaher & Zeinab Mahmoud. (2019) Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition. Anti-Cancer Agents in Medicinal Chemistry 19:11, pages 1368-1381.
Crossref
Paola Indovina, Francesca Pentimalli, Daniele Conti & Antonio Giordano. (2019) Translating RB1 predictive value in clinical cancer therapy: Are we there yet?. Biochemical Pharmacology 166, pages 323-334.
Crossref
Divya Vasanthakumari, Pushpa Vadakkethil Lalithabhai & Manoj Kanthimathi Bahuleyan. (2019) An in silico approach to discover the best molecular modeling strategy for designing novel CDK 4 inhibitors . Chemical Biology & Drug Design 93:4, pages 556-569.
Crossref
Elisa Ventura & Antonio Giordano. 2019. Reference Module in Life Sciences. Reference Module in Life Sciences.
Francesca Pentimalli, Iris M. Forte, Luca Esposito, Paola Indovina, Carmelina A. Iannuzzi, Luigi Alfano, Caterina Costa, Daniela Barone, Gaetano Rocco & Antonio Giordano. (2018) RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines. Oncogene 37:27, pages 3657-3671.
Crossref
Firli R.P. Dewi, Takahiro Domoto, Masaharu Hazawa, Akiko Kobayashi, Takayuki Douwaki, Toshinari Minamoto & Richard W. Wong. (2018) Colorectal cancer cells require glycogen synthase kinase-3β for sustaining mitosis via translocated promoter region (TPR)-dynein interaction. Oncotarget 9:17, pages 13337-13352.
Crossref
Peng Gao, Nicole A. Seebacher, Francis Hornicek, Zheng Guo & Zhenfeng Duan. (2018) Advances in sarcoma gene mutations and therapeutic targets. Cancer Treatment Reviews 62, pages 98-109.
Crossref
Tinghan Li, Tianwei Weng, Minzan Zuo, Zhihui Wei, Ming Chen & Zhiyu Li. (2016) Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents. Future Medicinal Chemistry 8:17, pages 2047-2076.
Crossref
Rosaria Chilà, Federica Guffanti & Giovanna Damia. (2016) Role and therapeutic potential of CDK12 in human cancers. Cancer Treatment Reviews 50, pages 83-88.
Crossref
Carmen Dominguez-Brauer, Kelsie L. Thu, Jacqueline M. Mason, Heiko Blaser, Mark R. Bray & Tak W. Mak. (2015) Targeting Mitosis in Cancer: Emerging Strategies. Molecular Cell 60:4, pages 524-536.
Crossref
Paola Indovina, Francesca Pentimalli, Nadia Casini, Immacolata Vocca & Antonio Giordano. (2015) RB1 dual role in proliferation and apoptosis: Cell fate control and implications for cancer therapy. Oncotarget 6:20, pages 17873-17890.
Crossref
Amel Hamdi, Aurélien Lesnard, Peggy Suzanne, Thomas Robert, Maria A. Miteva, Morgan Pellerano, Bruno Didier, Elizabeth Ficko-Blean, Annelise Lobstein, Marcel Hibert, Sylvain Rault, May C. Morris & Pierre Colas. (2015) Tampering with Cell Division by Using Small-Molecule Inhibitors of CDK-CKS Protein Interactions. ChemBioChem 16:3, pages 432-439.
Crossref
Marion Peyressatre, Camille Prével, Morgan Pellerano & May Morris. (2015) Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors. Cancers 7:1, pages 179-237.
Crossref
Camille Prével, Laetitia Kurzawa, Thi Nhu Ngoc Van & May C. Morris. (2014) Fluorescent biosensors for drug discovery new tools for old targets – Screening for inhibitors of cyclin-dependent kinases. European Journal of Medicinal Chemistry 88, pages 74-88.
Crossref
Yigong Shi. (2014) A Glimpse of Structural Biology through X-Ray Crystallography. Cell 159:5, pages 995-1014.
Crossref
Jonas Cicenas, Karthik Kalyan, Aleksandras Sorokinas, Asta Jatulyte, Deividas Valiunas, Algirdas Kaupinis & Mindaugas Valius. (2014) Highlights of the Latest Advances in Research on CDK Inhibitors. Cancers 6:4, pages 2224-2242.
Crossref
Thi Nhu Ngoc Van, Morgan Pellerano, Sophie Lykaso & May C. Morris. (2014) Fluorescent Protein Biosensor for Probing CDK/Cyclin Activity in vitro and in Living Cells. ChemBioChem 15:15, pages 2298-2305.
Crossref
Gaëlle Mariaule & Philippe Belmont. (2014) Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey. Molecules 19:9, pages 14366-14382.
Crossref
Todd M. Pitts, S. Lindsey Davis, S. Gail Eckhardt & Erica L. Bradshaw-Pierce. (2014) Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors. Pharmacology & Therapeutics 142:2, pages 258-269.
Crossref
Céline Bruyère & Laurent Meijer. (2013) Targeting cyclin-dependent kinases in anti-neoplastic therapy. Current Opinion in Cell Biology 25:6, pages 772-779.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.